Potent Alloimmune Modulation By Efalizumab in Islet Transplantation

Trial Profile

Potent Alloimmune Modulation By Efalizumab in Islet Transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2015

At a glance

  • Drugs Efalizumab (Primary) ; Belatacept
  • Indications Islet cell transplant rejection
  • Focus Pharmacodynamics
  • Most Recent Events

    • 22 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top